Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Non Operating Income: 2020-2025

Historic Other Non Operating Income for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $395,000.

  • Mirum Pharmaceuticals' Other Non Operating Income rose 136.34% to $395,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 22.40%. This contributed to the annual value of $1.2 million for FY2024, which is 102.47% up from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Other Non Operating Income stood at $395,000, which was up 359.30% from $86,000 recorded in Q2 2025.
  • Mirum Pharmaceuticals' Other Non Operating Income's 5-year high stood at $2.1 million during Q1 2025, with a 5-year trough of -$49.1 million in Q2 2023.
  • In the last 3 years, Mirum Pharmaceuticals' Other Non Operating Income had a median value of $271,500 in 2024 and averaged -$4.5 million.
  • Over the last 5 years, Mirum Pharmaceuticals' Other Non Operating Income had its largest YoY gain of 788.54% in 2023, and its largest YoY loss of 3,877.98% in 2023.
  • Mirum Pharmaceuticals' Other Non Operating Income (Quarterly) stood at -$17,000 in 2021, then plummeted by 3,358.82% to -$588,000 in 2022, then skyrocketed by 788.54% to $1.3 million in 2023, then tumbled by 182.22% to $231,000 in 2024, then soared by 136.34% to $395,000 in 2025.
  • Its Other Non Operating Income stands at $395,000 for Q3 2025, versus $86,000 for Q2 2025 and $2.1 million for Q1 2025.